These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18376247)

  • 1. 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
    Wynands J; Belbouab R; Candon S; Talbotec C; Mougenot JF; Chatenoud L; Schmitz J; Cézard JP; Goulet O; Hugot JP; Ruemmele FM
    J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):293-8. PubMed ID: 18376247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
    Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
    Steenholdt C; Molazahi A; Ainsworth MA; Brynskov J; Østergaard Thomsen O; Seidelin JB
    Scand J Gastroenterol; 2012 May; 47(5):518-27. PubMed ID: 22375898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term outcome of infliximab therapy in pediatric Crohn disease].
    Wanty C; Stephenne X; Sokal E; Smets F
    Arch Pediatr; 2011 Aug; 18(8):863-9. PubMed ID: 21723101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
    Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
    Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA
    J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease.
    Navarro FA; Hanauer SB; Kirschner BS
    J Pediatr Gastroenterol Nutr; 2007 Sep; 45(3):312-8. PubMed ID: 17873743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
    Ruemmele FM; Lachaux A; Cézard JP; Morali A; Maurage C; Giniès JL; Viola S; Goulet O; Lamireau T; Scaillon M; Breton A; Sarles J;
    Inflamm Bowel Dis; 2009 Mar; 15(3):388-94. PubMed ID: 19023899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
    Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA; Villela R; Silverberg MS; Greenberg GR
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of corticosteroids, immunomodulators, and infliximab at a third-level Day-Hospital Service of Gastro-Hepatology.
    Actis GC; Pellicano R; Bugianesi E; Lagget M; Rizzetto M
    Minerva Gastroenterol Dietol; 2008 Sep; 54(3):239-42. PubMed ID: 18614972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
    Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
    Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
    Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
    Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
    Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab for ulcerative colitis in children and adolescents.
    McGinnis JK; Murray KF
    J Clin Gastroenterol; 2008 Sep; 42(8):875-9. PubMed ID: 18645529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease.
    Taxonera C; Rodrigo L; Casellas F; Calvet X; Gómez-Camacho F; Ginard D; Castro M; Castro L; Ponce M; Martínez-Montiel P; Ricart E; Gisbert JP; López-San Román A; Morales JM; Casado MA
    J Clin Gastroenterol; 2009; 43(10):950-6. PubMed ID: 19448569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.
    Simonini G; Zannin ME; Caputo R; Falcini F; de Martino M; Zulian F; Cimaz R
    Rheumatology (Oxford); 2008 Oct; 47(10):1510-4. PubMed ID: 18676502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.